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Abstract
Background: HIV-1 uses cellular co-factors for virion formation and release. The virus is able to
incorporate into the viral particles host cellular proteins, such as tetraspanins which could serve to
facilitate HIV-1 egress. Here, we investigated the implication of several tetraspanins on HIV-1
formation and release in chronically infected T-lymphoblastic cells, a model that permits the study
of the late steps of HIV-1 replication.
Results:  Our data revealed that HIV-1 Gag and Env structural proteins co-localized with
tetraspanins in the form of clusters. Co-immunoprecipitation experiments showed that Gag
proteins interact, directly or indirectly, with CD81, and less with CD82, in tetraspanin-enriched
microdomains composed of CD81/CD82/CD63. In addition, when HIV-1 producing cells were
treated with anti-CD81 antibodies, or upon CD81 silencing by RNA interference, HIV-1 release
was significantly impaired, and its infectivity was modulated. Finally, CD81 downregulation resulted
in Gag redistribution at the cell surface.
Conclusion:  Our findings not only extend the notion that HIV-1 assembly can occur on
tetraspanin-enriched microdomains in T cells, but also highlight a critical role for the tetraspanin
CD81 on the late steps of HIV replication.
Background
Tetraspanins constitute a large family of membrane glyco-
proteins with four transmembrane domains which are
widely expressed in human cells. The tetraspanin family
comprises 33 different members, among which the most
studied are CD9, CD63, CD81, CD82 and CD151. These
proteins have a role in the regulation of many biological
processes such as cell-cell adhesion, fusion, signal trans-
duction, proliferation and differentiation [1,2]. The exact
mechanism by which these proteins function is still
poorly understood. Tetraspanins probably function in the
form of complexes since they interact with each other and
with different partners including transmembrane proteins
such as adhesion molecules, receptors and intracellular
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signalling/cytoskeletal proteins, creating a network of
interacting proteins called the tetraspanin web [3]. Their
ability to also interact with cholesterol has led to the con-
cept that tetraspanins might be organizers of specific lipid
microdomains which are referred to as tetraspanin-
enriched microdomains (TEMs) [4-6]. Tetraspanins also
play a role in the dissemination of pathogens that cause
malaria and diphtheria and in viral infections [7]. Moreo-
ver, several tetraspanins are involved in the life cycle of
certain viruses, beginning from their initial cellular attach-
ment and ending with virus production. In this respect,
CD81 is probably the best known example in its role as a
binding partner of the E2 envelope protein of HCV [8,9].
Recent investigations have focused on the involvement of
tetraspanins in human immunodeficiency virus type 1
(HIV-1) assembly. In fact, HIV-1 assembly has been
shown to take place mainly at the plasma membrane, but
also in multivesicular body (MVB)/late endosomes [10-
20], even though this latter location for HIV-1 has been
recently challenged by investigators who reported that the
endosomal HIV-1-containing compartments in macro-
phages could actually be deep invaginations of the plasma
membrane [21,22]. Nevertheless, it remains that HIV-1
assembly seems to favour tetraspanin-enriched microdo-
mains (TEMs) [12,21,16,23]. Tetraspanins can be found
at the cell surface and in intracellular compartments:
CD63, which possesses an interacting motif with the
adaptor AP-3 protein, is mainly targeted to the endocytic
pathway [24] while most of the other tetraspanins are
found both at the plasma membrane and in intracellular
vesicles [25]. Indeed, late endosomes/MVBs are highly
enriched in the tetraspanins CD9, CD63, CD81, and
CD82, which contribute to their fusion with the plasma
membrane and the release of 50–90 nm vesicles called
exosomes that resemble viral particles [26,25,27].
If HIV-1 assembly takes place on tetraspanin-enriched
microdomains (TEMs), proteins from these domains
would be expected to be incorporated during virus forma-
tion into newly made virions. In agreement with this
notion, HIV-1 budding structures and newly made HIV-1
particles can be labeled by anti-CD63 antibodies, as
shown by immuno-electron microscopy [14,28,29]. We
previously reported the association of CD63 with HIV-1
particles and HIV-1-containing compartments in an
infected T-lymphoblastic cell line [14]. In addition,
CD63, found mainly in MVBs, is incorporated into HIV-1
virions [12,14,20,30]. Yet, recent works have reported a
contradictory role of CD63 on the late steps of HIV repli-
cation in macrophages [31,32].
It was thus proposed that HIV-1 exploits the exocytic
vesicular pathway for its assembly and budding. However,
CD81 was also found to co-localize with HIV-1 Gag pro-
tein at the surface of Jurkat T cells and in exosomes [12],
as well as with HIV-1 virions accumulated in CD81 and
CD9 enriched intracellular compartments of dendritic
cells [33]. Finally, a recent report showed that CD63 and
CD81 are recruited within the virological synapse and
contributed to the formation of this structure [16]. These
findings indicate that CD63, CD81 and possibly other tet-
raspanins can be involved in HIV-1 assembly, but their
precise role in HIV-1 biogenesis remains to be deter-
mined.
To address this question, we investigated the relationships
between Gag, which is the major structural polyprotein of
HIV-1, and several tetraspanins such as CD9, CD63,
CD81 and CD82 in chronically infected T lymphoblastic
cells (MOLT/HIV-1 cells). This cell line appears to be a
good model to study the last steps of the virus life cycle
because the expression of CD4, the HIV-1 receptor, is
downregulated below detectable level; thus, this lack of
CD4 should prevent reinfection of the cells. We have pre-
viously reported in MOLT/HIV-1 cells a phenotype atypi-
cal of HIV-1 infected T cells in which there is a high level
of late endosome-associated viral particles [14]. By means
of confocal microscopy imaging, viral and cellular biology
technics, we report that in the MOLT/HIV-1 cell line, there
is a clustering of the tetraspanins CD63, CD81 and CD82
together with the viral structural proteins Gag and Env. In
addition, the latter tetraspanins co-purified with HIV-1
virions. However, not all of the tetraspanins seem to have
a critical role in HIV-1 formation since our results showed
that intracellular Gag protein was part of protein com-
plexes containing mainly CD81 and much less CD82, sug-
gesting a possible major role of CD81 in virus assembly.
As a consequence, CD81 and limited CD82 were incorpo-
rated in purified HIV-1 virions. Finally, when HIV-1 pro-
ducing cells were treated with anti-CD81 antibodies, or
when CD81 was downregulated by RNA interference,
HIV-1 production was impaired and Gag became evenly
distributed at the cell surface.
Our results show that HIV-1 assembly can occur on tet-
raspanin-enriched microdomains in MOLT/HIV-1 cells
and that the tetraspanin CD81 recruited in the viral parti-
cles plays a critical role in the late steps of HIV-1 replica-
tion.
Materials and methods
Cell culture
Chronically HIV-1NL4-3 infected MOLT lymphocytes were
used in this study and were a kind gift of J. Esté (University
of Barcelona, Spain). Parental MOLT-4 cells are prototype
lymphoid T cells (NIH AIDS reagent program, USA) and
were infected with HIV-1NL4-3  to generate chronically
infected MOLT cells. These cells are negative for CD4 as
measured by flow cytometry. MOLT/HIV-1 and SupT1 (T-Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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lymphocitic cell line) cells were grown in RPMI supple-
mented with 10% fetal calf serum (FCS) and antibiotics.
Antibodies
Immunoblotting, immunostaining, immunoprecipita-
tions and cell surface tetraspanin "depletion" were per-
formed using the following antibodies: rabbit anti-
MAp17, mouse anti-CAp24, mouse anti-TMgp41, human
anti-SU gp120 (NIH, USA), the mouse monoclonal anti-
bodies anti-Lamp2 (H5G11), anti-Lamp3/CD63 (MX-
49.129.5), anti-CD81 (5A6), anti-GAPDH (6C5), (Santa
Cruz Biotechnology Inc.), anti-CD45 (HI30) (BD
Pharmingen). Anti-CD9 (Syb1), anti-CD63 (TS63) and
anti-CD81 (TS81) were mouse IgG1 antibodies from
ascitic fluids, and were kind gifts from E. Rubinstein. Anti-
CD82 (alphaC11) was a purified mouse IgG1 antibody (2
mg/ml). Anti-VsV-g (P5D4) was used as an irrelevant anti-
body. For immunofluorencence staining, fluorescent
Alexa® 488, 546 and 633-conjugated secondary antibodies
were used (Molecular Probes).
Immunofluorescence staining and confocal microscopy 
imaging
MOLT/HIV-1 cells were harvested by centrifugation,
washed once in PBS, and fixed in 3% paraformaldehyde-
PBS for 20 minutes. The fixative was then removed, and
free aldehydes were quenched with 50 mM NH4Cl. The
necessary cells were then permeabilized using 0.2% Triton
X-100 for 5 minutes and blocked in 1% BSA-PBS. The
fixed cells were incubated for one hour at room tempera-
ture with primary antibodies, washed 3 times with 1%
BSA-PBS, and further incubated for 1 hour with the corre-
sponding secondary fluorescent antibodies. The slides
were mounted with Mowiol (Sigma). Images were
acquired on Axioplan 2 Zeiss CLSM 510 confocal micro-
scope with Argon 488/458, HeNe 543, HeNe 633 lasers
and plan apochromat 63 × 1.4 oil objective, supplied with
LSM 510 3.4 software. Co-localization between Gag and
cellular markers was determined using the MetaMorph®
OffLine 7.0 Software.
Virion purification and immunoblotting
HIV-1 virions produced by MOLT/HIV-1 cells were puri-
fied by pelleting through a double layer of 25%–45%
sucrose cushion in TNE (Tris 10 mM, NaCl 100 mM,
EDTA 1 mM) at 28,000 rpm for 1 hour and 15 minutes in
a SW28 Beckman rotor. The 5 ml sucrose-cushion inter-
phases containing the virions were collected and diluted
in PBS. The virions were further purified by another ultra-
centrifugation through a 25% sucrose-TNE cushion, and
resuspended in TNE.
Viral pellets or cell lysates (50 μg of total cellular proteins
per lane) were separated on 10% SDS-PAGE and detected
by immunoblotting with primary and secondary antibod-
ies as follows: mouse anti-CAp24, mouse anti-Lamp2,
anti-Lamp3, anti-CD81, anti-CD9, anti-CD82 and anti-
CD45. Corresponding horse-radish-peroxidase (HRP)
conjugated immunoglobulins (DakoCytomation) were
used and the signal was detected using SuperSignal® West
Pico Chemiluminescent Substrate (Pierce).
Sucrose gradient fractionation
Viral pellets from MOLT/HIV-1 were resuspended and lay-
ered on top of a discontinuous sucrose gradient (20–
60%) and ultracentrifuged for 18 hours at 25,000 rpm in
SW41 rotor. 500 μl fractions were collected and measured
for density using a refractometer. All fractions were ana-
lysed for the presence of virus particles both by exogenous
reverse transcriptase (RT) activity and by immunoblotting
with anti-CAp24 and anti-TMgp41 antibodies. The frac-
tions were analyzed by immunoblotting and for the pres-
ence of tetraspanins and other cellular proteins as already
described.
Reverse Transcriptase assay
RT activity of viral immunoprecipitated supernatant was
measured using the following procedure: 12 μl of virus
containing supernatant were incubated in a mix contain-
ing 48.75 μl of RT buffer (60 mM Tris pH 8.0, 180 mM
KCl, 6 mM MgCl2, 0.6 mM EGTA pH 8.0, 0.12% Triton
X100), 0.3 μl of 1 M DTT, 0.16 μl of 2 mg/ml oligo dT, 0.6
μl of 1 mg/ml poly rA and 0.25 μl of alpha32P dTT for 1 h
at 37°C. Afterwards, 5 μl of this reaction were deposited
on a Whattman paper, and the latter was quickly washed
twice with 2 × SSC (0.3 M NaCl, 0.03 M sodium citrate pH
7.0) and then once more for 15 minutes. The membrane
was exposed on a phosphor screen and read using a phos-
phorimager.
Immunoprecipitation of HIV-1 virions
For each virus immunoprecipitation experiment, the
appropriate quantity of antibody (2 μg for anti-CD9,
CD63, CD81 and CD82, 1.5 μg for anti-CD45 and anti-
tubulin and 3 μl for human anti-HIV serum) was mixed
with 50 μl of Protein G Sepharose™ beads, and incubated
for 1 hour on ice. Purified HIV-1NL4-3 virions (107 virions/
sample) produced by chronically infected MOLT cells
were diluted in 200 μl of 0.1% BSA-PBS and were mixed
with 12 μl of Protein G Sepharose™ beads and incubated
for 1 hour at 4°C on a wheel. After centrifugation, the pre-
cleared virions were added to Protein G Sepharose™ beads
coupled with different antibodies and incubated for 4
hours at 4°C on a wheel. Then after centrifugation, the vir-
ion-coupled-beads were washed 3 times in PBS and resus-
pended in reducing electrophoresis buffer for a SDS-PAGE
analysis. Immunoprecipitated virus was detected by
immunoblotting using an anti-CAp24 (rabbit, from Aids
Reagent Program) antibody and an anti-mouse HRP-con-
jugated antibody.Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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Intracellular immunoprecipitation
Proteins from 4.10^7 cells were solubilized in 1 ml TBS-
CHAPS (Tris/HCl 50 mM + 150 mM NaCl + 1 mM CaCl2
+ 1 mM MgCl2, pH 7.4), supplemented with 1% CHAPS
and protease inhibitors. After a preclearing step of 2 hours
incubation with 50 μl Protein G Agorose beads (Roche
Diagnostic), cell lysates were incubated overnight at 4°C
with 2 μg of immunoprecipating antibodies (anti-CD82,
anti-CD81, anti-CD63, anti-CD9 or control antibody
(anti-GAPDH or anti-CD71) and 2 hours with Protein G-
Agarose beads (50 μl/IP). Immunoprecipitated materials
(obtained after 5 washes in TBS-CHAPS) were solubilized
in 50 μl of 1× sample buffer without reducing agent, while
supernatants were diluted 10 times in 1.1 sample buffer.
After 10 minutes boiling, proteins were separated by 12%
SDS-PAGE and transfered on PVDF membranes. The
membranes were incubated with blocking buffer TBST
(TBS 1× + 0.1% Tween 20) + 5% non-fat milk and then
with mouse anti-CD82 or rabbit anti-CAp24. After 5
washes in TBST supplemented with 1% skim milk, mem-
branes were incubated with HRP-secondary antibodies
(anti-mouse or anti-rabbit), washed extensively (5 times)
and probed with ECL+ Western blotting detection kit
(Amersham).
FACS analysis
For cell surface analysis, MOLT/HIV-1 cells were incu-
bated for 30 minutes at 4°C with a saturating concentra-
tion of antibodies directed against CD81 and CD45 in
PBS 5% FCS. An irrelevant antibody was also used as a
staining control. After 2 washes in PBS 5% FCS, cells were
fixed in PBS 3% PFA for 10 minutes and washed once.
Then goat anti mouse -Phyco-erythrine (PE) labeled
(GAM-PE) was used as a secondary antibody (Santa Cruz
Biotechnology Inc). For overall staining, cells were fixed,
stained and permeabilized with the Fix and Perm® cell per-
meabilization reagents, according to manufacturer's
instructions, then GAM-PE was used as a secondary anti-
body. For Fig. SixB, directly PE-conjugated antibodies
against CD81 (JS-81) or CD45 (HI30) from BD-Phar-
magen were used at a saturating concentration. Data
acquisition and analysis were performed with FACS cali-
bur flow cytometer equipped with CellQuest Pro software
(BD Biosciences).
CD81 silencing using lentivectors and infectivity
Lentivectors were produced as follow: 293T cells were
transfected with the plasmids expressing the envelope
VSV-G, the HIV-1 Gag-Pol [34] and the shRNA directed
against CD81 (UCAUGAUGUUCGUUGGCU) or the con-
trol shRNA (GACCCCCUUGTGAAUCUC). GFP was
included as a marker in the lentivector (a kind gift of Birke
Bartosch, Inserm#758, ENS de Lyon, France). Vectors are
derived from [35]. Lentivector particles were collected 48
hours post-transfection and purified by ultracentrifuga-
tion on a 25% sucrose cushion. The virus titer was deter-
mined by measuring GFP expression in HeLa cells by
FACS analysis. The same amount of VLPs was used to
transduce MOLT/HIV-1 cells at a multiplicity of infection
(MOI) of 2 for 72 hours. Then cells were washed in PBS
and resuspended in a new medium for 6 hours to let de
novo  release of HIV-1. Fifteen μl of HIV-1 containing
supernatant were collected for an RT test, and the rest was
purified by spinning at 2000 rpm/5 min and ultracentri-
fuged afterwards at 50 000 rpm/2 h/4°C in a TL-100 rotor
and analysed by immunoblotting. One part of the cells
was analyzed by flow cytometry (for GFP expression to
monitor transduction efficiency, and to monitor for CD81
downregulation). The remaining cells were lysed in RIPA,
sonicated and 70 μg of total protein were analysed by
immunoblotting.
For infectivity measurement, 10 μl of each virus pellet,
produced by shRNA treated cells, were added to SupT1
cells and incubated overnight. Afterwards cells were
washed using PBS and were resuspended in new medium
for 6 days. When syncytia formation occurred, the cell
supernatants were collected and de novo virus production
was measured to determine infectivity by exogenous RT
activity. Results were normalized after taking into account
of the initial RT activity of the viral innoculum.
Results
Localization of tetraspanins and viral proteins in HIV-1 
infected T cells
We analyzed by immuno-confocal microscopy the influ-
ence of HIV-1 infection of MOLT T lymphoblastic cells
(MOLT/HIV-1) on the cellular distribution of several tet-
raspanins, such as CD9, CD63, CD81 and CD82, in com-
parison with other membrane proteins, such as the CD45
tyrosine phosphatase, which is known as a marker of the
plasma membrane [36], and Lamp2 which is a lysosome-
associated membrane protein [37].
In a first series of experiments, MOLT/HIV-1 cells were
surface labelled with specific antibodies against viral and
cellular proteins without permeabilization of the cell
membrane (Fig. 1). At the cell surface of MOLT/HIV-1
cells, CD81 co-localized with both Gag and Env in dis-
crete plasma membrane clusters while CD63 and CD82
mainly co-localized with Gag and partially with both Gag
and Env (Fig. 1, merge in white color). CD45 remained
evenly distributed at the cell surface and only sometimes
co-localized with Gag and Env. In contrast, both CD9 and
Lamp2 were undetectable (Fig. 1). One could notice that
in the absence of permeabilization, some Gag protein was
found at the cell surface. This might be explained by the
fact that cell fixation by PFA can partially permeabilized
cells or viruses at the cell surface rendering Gag accessible
to the antibody even if Gag molecules are within the viri-Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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Localization of HIV-1 Gag and Env with tetraspanins at the cell surface of HIV-1 infected MOLT cells Figure 1
Localization of HIV-1 Gag and Env with tetraspanins at the cell surface of HIV-1 infected MOLT cells. MOLT/
HIV-1 cells were fixed and the cell surface was stained directly with the anti-tetraspanin CD9, CD63, CD81 or CD82 antibod-
ies, or with antibodies against CD45 or Lamp2. To reveal the viral proteins Gag and Env, the cells were co-stained with anti-
MAp17 (Gag in green) and anti-SU gp120 (Env in red) antibodies. It can be observed that the tetraspanins are localized in 
microdomains close to or at the cell periphery. The percentage of Gag co-localization with the markers was calculated by 
image analysis and reported in the graph (Fig. 3).
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ons that are departing the cell as shown by electron micro-
scopy [14].
In a second series of experiments, we compared the over-
all distribution after cell permeabilization of the same cel-
lular proteins and HIV-1 Gag and Env (Fig. 2). Unlike the
surface staining, permeabilization showed that Gag and
Env fully co-localized with CD63, CD81 and CD82. Sur-
prisingly, CD9, which was not detected at the cell surface
(Fig. 1), was found in intracellular compartments and co-
localized with HIV-1 Gag and Env in clusters near the
plasma membrane. No co-localization was observed with
Lamp2, suggesting that the tetraspanin/HIV-1 enriched
intracellular compartments did not correspond to lyso-
somes. A partial co-localization of Gag and Env appeared
with the CD45 plasma membrane protein.
Quantification of Gag co-localization with tetraspanins
revealed that Gag was mainly distributed within CD81
and CD82 labelled microdomains for non-permeabilized
cells (i.e. 80% of Gag co-localized with CD81 and CD82,
and 40% and 30% with CD63 and CD45, respectively),
and within CD9, CD81 and CD82 labelled microdomains
upon cell permeabilization (i.e. between 40–80% of Gag
co-localized with CD9, CD63, CD81 and CD82 tet-
raspanins, and only 20% with the CD45 cell surface pro-
tein) (Fig. 3).
Altogether, these results indicate that Gag and Env co-
localized mainly with the tetraspanins CD81, CD82 and
less often with CD63 in membrane microdomains (called
TEM complexes) or near the cell surface, but very little
with other membrane proteins like Lamp 2 and CD45.
Co-fractionation of Purified HIV-1 virions with 
tetraspanins
To explore the functional relationship between HIV-1
assembly and TEMs, we investigated the possible incorpo-
ration of tetraspanins into progeny virions.
Particles produced by MOLT/HIV-1 cells were purified,
and total viral proteins were analyzed for the presence of
tetraspanins by immunoblotting (Fig. 4A). All proteins of
interest were present in the cell lysates (Fig. 4A). However,
we found that the tetraspanins CD81, CD63 and CD82
were present in the virus-containing pellet, while CD9 was
not. The membrane protein Lamp2 was not found in the
viral pellet, in agreement with the data obtained by
immuno-confocal analysis. Only the cell surface marker
CD45 was slightly detected in the virus-containing pellet
(Fig. 4A).
To confirm the presence of tetraspanins in HIV-1 virions,
we performed a more stringent purification by running
the already purified virions on a sucrose density gradient
(Fig. 4B) (see Materials and Methods). The fractions were
analyzed for density, RT activity and relative amounts of
different cellular membrane and viral proteins. RT activity
(data not shown), and the CAp24 and TMgp41 proteins
(Fig. 4B, lane 11–15) were found in fractions where HIV-
1 virions are known to sediment (density of 1.15 – 1.18 g/
ml) [38,39]. Large amounts of CD63, CD81 and CD82 co-
sedimented with HIV-1 (Fig. 4B – left panel, lane 11–14),
while CD9 and Lamp2 did not. In a mock gradient ("pel-
let" from uninfected MOLT cells, Fig. 4B – right panel), no
signal was obtained for any of the tetraspanins indicating
that they were not secreted from the cells in a pelletable
form. Interestingly, CD81 and CD82 were also detected in
a slightly lighter density fraction (lane 10), which could
be due to their high cell surface expression and/or the
potential contamination of viral particles by plasma
membrane microdomains of a lighter density. In fact,
contamination of HIV-1 sucrose density-equilibrium gra-
dients with plasma membrane derived vesicles (microves-
icles) has been previously observed [40-42]. CD45, which
is an abundant cell surface protein was identified as a
molecule that is highly expressed on microvesicles, but
not found in HIV-1 virions [40]. The fact that CD45 was
hardly detected (Fig. 4B, lane 12–14), suggests that these
fractions contain only minimal amounts of microvesicles.
We cannot completely exclude the presence of exosomes
in the virus fractions because their range of sedimentation
may vary from 1.08 to 1.22 g/ml [43] which overlaps with
the HIV-1 virion density. However, CD9, which accumu-
lates in exosomes [44,26,27], was not found in the gradi-
ent, indicating a minimal contamination (if any) of the
purified virions by exosomes.
Thus, we observed that CD81, CD82, and CD63, were
associated with HIV-1 virions produced by infected T-lym-
phoblastic cells.
Anti-tetraspanin antibodies immunoprecipitate HIV-1 
virions
As a complementary approach to document the incorpo-
ration of tetraspanins in HIV-1 virions, we examined
whether anti-tetraspanin antibodies could immunopre-
cipitate purified HIV-1 virions. For this purpose, virus
preparations were incubated with anti-tetraspanin anti-
bodies coupled to Sepharose-G beads, and the viral con-
tent of the immunoprecipitated material was analyzed by
immunoblotting (Fig. 4C). The anti-CAp24 immunoblot
revealed that viral particles were immunoprecipitated
from purified virus using an HIV-1 serum and anti-Env
gp120 (Fig. 4C, lane 1 and 2), and anti-CD81 (lane 7)
antibodies. A weak signal appeared using an anti-CD82
antibody (lane 8). No signal was detected in immunopre-
cipitates from the mock sample ("vesicles" of uninfected
cells, data not shown), which indicates that the antibodies
used for immunoprecipitation did not cross-react with theRetrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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Localization of HIV-1 Gag and Env with tetraspanins in permeabilized HIV-1 infected MOLT cells Figure 2
Localization of HIV-1 Gag and Env with tetraspanins in permeabilized HIV-1 infected MOLT cells. MOLT/HIV-1 
cells were fixed, permeabilized, and stained with the anti-tetraspanin CD9, CD63, CD81 or CD82 antibodies, or with antibod-
ies against CD45 or Lamp2. To reveal the viral proteins Gag and Env, the cells were co-stained with anti-MAp17 (Gag in green) 
and anti-SU gp120 (Env in red) antibodies. The percentage of Gag co-localization with the markers was calculated by image 
analysis and reported in the graph (Fig. 3).
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
Page 8 of 16
(page number not for citation purposes)
anti-CAp24 antibody. Non-specific immunoprecipitation
of the virus was under the threshold of detection since no
band was observed in the absence of antibody (lane 3), or
with antibodies against CD45 (lane 4) or CD9 (lane 5).
Although CD63 was detected in the viral pellet (Fig. 4A
and 4B), no CAp24 was detected in the CD63 immuno-
precipitate (lane 6). We can speculate that even though
CD63, CD81 and CD82 are associated with HIV-1 virions,
only CD81 is well incorporated into the particle, which
can be due to its tight interaction with HIV-1 proteins dur-
ing assembly.
HIV-1 Gag proteins form intracellular complexes with 
tetraspanins in MOLT/HIV-1 cells
Since we found that CD81, and to a lesser extent CD82,
were incorporated into newly made virions, we analyzed
whether HIV-1 Gag proteins could associate with these
tetraspanins in infected T cells (Fig. 5). MOLT/HIV-1 cells
were lysed using a mild detergent and proteins were
immunoprecipitated with antibodies directed against
CD63, CD81, CD82 or with a control antibody. After
SDS-PAGE under non-reducing conditions, membranes
were blotted with an anti-CAp24 (bottom) or with an
anti-CD82 (top) antibody. Figure 5 (bottom) shows that
anti-CD81 antibodies clearly precipitated the Pr55Gag
precursor and the mature CAp24, while background levels
were detected with the control antibody and with anti-
CD63. The Pr55Gag and CAp24 proteins were also
slightly detected upon immuno-precipitation with anti-
CD82. Blotting the same immunoprecipitates with an
anti-CD82 antibody (Fig. 5, top) showed that the mild
lysis conditions used maintained the tetraspanin web
association since a significant amount of CD82 was recov-
ered together with CD81 and CD63.
These data reveal that intracellular HIV-1 structural Gag
proteins can strongly associate with CD81, and less with
CD82, highlighting a potential role for CD81 in virus
assembly. This result may also explain why we could not
detect CD63, and very little CD82, in HIV-1 virions by
immunoprecipitation (Fig. 4C).
CD81 tetraspanin segregation from the cell surface 
impairs HIV-1 release
To evaluate the functional impact of Gag/tetraspanin
interaction, we investigated the consequences of anti-tet-
raspanin antibody treatment on HIV-1 release. MOLT/
HIV-1 cells were incubated with anti-tetraspanin antibod-
ies for 1 hour, and virus release was monitored 3 hours
post-treatment. This procedure can trigger either tet-
raspanin internalization [45] or fix tetraspanins on TEM at
the cell surface and render them unable to function. We
found that anti-CD81 antibodies decreased HIV-1 release
by 3-fold (Fig. 6A). A lower effect was observed after cell
treatment with anti-CD82, and practically no effect was
seen with anti-CD9, anti-CD63 or with anti-VSVg, anti-
Lamp2 or anti-CD45 control antibodies (Fig. 6A).
Flow cytometry analysis showed that one hour of incuba-
tion of MOLT/HIV-1 cells with anti-CD81 or anti-CD45
antibodies, even 3 hours after the treated cells were
washed, caused a significant disappearance or inaccessi-
bility of CD81 and CD45 from the cell surface (Fig. 6B).
However, in contrast to the anti-CD81 results, anti-CD45
had no effect on virus release.
Following anti-CD81 treatment of the MOLT/HIV-1 pro-
ducer cells, infectivity of those virions (normalized by RT
activity) was about 2–3-fold higher as compared with vir-
ions from untreated MOLT/HIV-1 cells (Fig. 6C). Thus,
the presence of CD81 on the virus could modulate its
infectivity in cell culture in accordance with the recent
data of Sato and collaborators (47) who reported a similar
effect of other tetraspanins on HIV-1 infectivity.
Lastly, we examined Gag processing upon producer cell
treatment with different anti-tetraspanin antibodies (Fig.
6D). We found that Gag maturation remained
unchanged. In addition, there was retention of mature vir-
ions (as seen by the matured capsid CAp24) in producer
cells treated with anti-CD81 consistent with the fact that
there was less virus produced in the presence of an anti-
CD81 antibody (Fig. 6D, lane CD81).
Localization of HIV-1 Gag and Env with tetraspanins in HIV-1  infected MOLT cells Figure 3
Localization of HIV-1 Gag and Env with tetraspanins 
in HIV-1 infected MOLT cells. The percentage of Gag co-
localization with the tetraspanins or the CD45 or Lamp2 
proteins was calculated by image analysis by the MetaMorph® 
Software and reported in the graph. Quantifications in non 
permeabilized MOLT/HIV-1 cells are indicated in black color, 
and in permeabilized cells in grey color, as indicated.
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Taken together, these results suggest that an optimal HIV-
1 particle production is dependent on the presence of
functional or accessible CD81 in HIV-1 producing T lym-
phoblastic cells.
CD81 tetraspanin silencing causes a partial inhibition of 
HIV-1 production and modulates virus infectivity
To further investigate the effects of CD81 on HIV-1 pro-
duction and infectivity, we silenced its expression in
MOLT/HIV-1 cells using a lentivector (LV) expressing a
shRNA directed against CD81. For this purpose, we trans-
duced the cells with an HIV-1 based LV that encodes either
a shRNA against CD81 or an irrelevant shRNA (control).
Three days post LV transduction, the level of intracellular
GFP expression reached 99% in both cell cultures show-
ing a high level of cell transduction. We thus measured
HIV-1 release in the cell supernatant by RT assay (Fig. 7A)
and analysed the total cellular expression of Gag, CAp24
and CD81 by immunoblotting (Fig. 7B). Our results
showed that in the CD81 shRNA transduced cells the level
of expression of CD81 was three times lower than in the
control cells (based on the mean fluorescence index as
measured by FACS analysis – data not shown) and was
barely detectable by immunoblotting (Fig. 7B). HIV-1
production by these cells was decreased by 70% (3-fold)
as compared to cells transduced with the control LV-
shRNA (Fig. 7A and 7B).
Virus production and CD81 silencing in the cells were
analyzed by immunoblotting (Fig. 7B). Both virus release
and CD81 level were strongly reduced in the shCD81
treated cells (Fig. 7B) showing that an efficient silencing of
CD81 can lead to an important reduction of HIV-1 parti-
cle production. At the same time, LV infection of these
cells did not have an effect on the intracellular expression
of HIV-1 Gag or actin.
This result showed that the downregulation of CD81 by
an interfering shRNA significantly impairs HIV-1 release.
Furthermore, the resulting virus issued from CD81
silenced MOLT/HIV-1 cells was tested for infectivity on
SupT1 cells, as compared with the virus issued from
shRNA control cells (Fig. 7C). Upon normalization of the
virus by RT activity, we observed that HIV-1 produced by
CD81 silenced cells was about 2.5 fold more infectious
than the virus produced by control LV-treated MOLT/HIV-
1 cells, suggesting that CD81 can modulate virus infectiv-
ity in cell culture.
Downregulation of CD81 results in Gag redistribution at 
the cell surface
Down modulation of CD81 expression in MOLT/HIV-1
producer cells prompted us to examine by immunofluo-
rescence microscopy Gag distribution in these cells ("sh
CD81") and in control LV treated MOLT/HIV-1 cells ("sh
control") (Fig. 7D). There are two major Gag distribu-
tions, namely in clusters at the cell surface ("clustered")
and in a punctated form all over the cell periphery ("dis-
persed"). In CD81(+) cells, Gag appeared mainly clus-
tered (~60% showed clustering and ~40% punctated),
while in CD81(-) cells, Gag was mainly punctated (in
more than 75% of the cells, Gag appeared in a punctated
pattern at the cell surface).
This observation suggests that CD81 is required for the
organization of HIV-1 Gag within functional TEMs which
would favour HIV-1 assembly, release, and possibly trans-
mission via the virological synapse [16,46].
Discussion
This study was aimed at investigating the role of tet-
raspanins in the late steps of HIV-1 replication in chroni-
cally infected T cells (MOLT/HIV-1), one of the several
chronically infected cell systems to study HIV-1 assembly
[14]. In this work, we examined the putative association
of HIV-1 with cellular tetraspanins such as CD9, CD63,
CD81 and CD82, that can be found in endosomal and cell
surface membranes of T cell lines. We found that HIV-1
Gag and Env structural proteins co-localized with these
The tetraspanins CD63, CD81 and CD82 are associated with purified HIV-1 virions Figure 4 (see previous page)
The tetraspanins CD63, CD81 and CD82 are associated with purified HIV-1 virions. (A). Cell lysate from MOLT/
HIV-1 cells was run on SDS-PAGE and probed with antibodies against CD45, CD9, CD63, CD81, CD82, and Lamp2 as indi-
cated ("cells"). Purified viral pellet from MOLT/HIV-1 was immunoblotted with the same antibodies ("virus"). (B). Purified viri-
ons produced by MOLT/HIV-1 cells (left panel) were loaded on 20–70% sucrose density gradient. After ultracentrifugation at 
equilibrium, the gradient was fractionated and the density (g/ml) of each fraction was determined, as indicated. Immunoblots of 
all fractions were performed using antibodies against Gag and Env, the tetraspanins CD63, CD81, CD82, or CD9, and CD45 
or Lamp2 as controls. HIV-1 virions, as seen by the CAp24 and TMgp41, appeared in fractions with a density between 1.15–
1.17 g/ml. In the same viral fractions, signals were obtained for the tetraspanins CD63, CD81 and CD82. Control gradient 
from uninfected MOLT cells is presented on the right panel. (C). Purified HIV-1 virions from MOLT/HIV-1 were submitted to 
immunoprecipitation with CD45, CD9, CD63, CD81 and CD82 antibodies (lane 4 to 7), or with HIV-1 serum and Env gp120 
antibody as positive controls (lane 1 and 2) or without antibody as a negative control (No Ab – lane 3). Immunoprecipitated 
virions were run on SDS-PAGE gels and revealed with an anti-CAp24 antibody.Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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tetraspanins, but only CD63, CD81 and CD82 clustered at
the cell surface together with the major viral structural
proteins (Figs. 1, 2 and 3). These tetraspanins co-purified
with HIV-1 virions, but only anti-CD81 and anti-CD82
antibodies were able to immunoprecipitate viral particles
(Fig. 4). We were unable to immunoprecipitate HIV-1 vir-
ions with an anti-CD63 antibody in contrast to previous
studies which reported anti-CD63 mediated immunopre-
cipitation of HIV-1 particles that were produced by mac-
rophages (19, 20). In agreement with our data, Gag
containing TEMs of MOLT/HIV-1 cells showed only a low
level of CD63 (Fig. 5).
Next, we showed that intracellular Gag and capsid
(CAp24) proteins were engaged in complexes with CD81,
and much less with CD82, suggesting that HIV-1 proteins
specifically interact, directly or indirectly, with CD81,
which is part of a CD81/CD82/CD63 TEM in infected
MOLT/HIV-1 cells (Fig. 5). This result is consistent with
the fact that purified HIV-1 virions produced by these cells
contain CD81, implying that CD81 might have a role dur-
ing HIV-1 assembly in MOLT/HIV-1 cells. In agreement
with this, incubation of MOLT/HIV-1 cells with an anti-
CD81 antibody significantly impaired virus release (Fig.
6). Moreover, silencing CD81 expression by shRNA also
resulted in a partial inhibition of viral particle production
(Fig. 7).
Nyddeger and collaborators were the first to propose that
tetraspanin-enriched microdomains (TEMs) can function
as gateways for HIV-1 egress in HeLa cells [47]. This was
also found to occur in macrophages [21] and in HIV-1
infected Jurkat T cells [16]. We previously reported that in
MOLT/HIV-1 cells, viral particles and intracellular Gag
can associate with the CD63 tetraspanin [14]. Our last
findings showed that in these T cells, HIV-1 assembly can
occur on TEMs (i.e. that Gag proteins use TEMs, com-
posed at least of CD81/CD82/CD63), as a platform for
particle assembly with a notable interaction, direct or
indirect, between Gag and CD81.
CD82 could have been a good candidate for Gag assembly
as it was found to co-localize with intracellular Gag and
Env (Figs. 1, 2 and 3); however, an anti-CD82 antibody
had a very moderate effect at immunoprecipitating intra-
cellular Gag or inhibiting HIV-1 release. Either the tar-
geted epitope of the anti-CD82 is less accessible or there is
no major functional role for CD82 in virus formation
and/or release, in comparison with CD81. Indeed, several
monoclonal anti-tetraspanin antibodies were tested and
were able to reproduce the results shown in Fig. 6 (data
not shown). Thus only the effect of CD81 downregulation
in MOLT/HIV-1 cells was investigated on HIV-1 release
and infectivity. We showed that CD81 downregulation
decreased virus production by 3-fold (Fig. 7A, B) and the
resulting virus was more infectious (Fig. 7C), suggesting
that CD81 tetraspanin incorporation is able to modulate
HIV-1 infection, as this was recently proposed for HIV-1
infected CD4+ activated lymphocytes [48].
Thus one has to understand how CD81 segregation in
TEM favors Gag assembly and release, and at the same
time CD81 incorporation into virion renders viruses less
infectious. In fact, the high concentration of Gag in TEM
should certainly accelerate virus assembly at one cell pole
(Fig. 7D), resulting in the favoring of HIV-1 transmission
by cell-cell contacts via the virological synapse [16,46].
HIV-1 Gag proteins form intracellular complexes with endog- enous CD81 and CD82 tetraspanins Figure 5
HIV-1 Gag proteins form intracellular complexes 
with endogenous CD81 and CD82 tetraspanins. Cell 
lysates from MOLT/HIV-1 cells were immunoprecipitated 
with antibodies directed against CD81, CD63 and CD82 or a 
control antibody. Non-immunoprecipitated (supernatants) or 
immunoprecipitated (IP) proteins were resolved by SDS-
PAGE and blotted with an anti-HIV-1 human serum or an 
anti-CD82 antibody as indicated. The positions of Gag prod-
ucts and CD82 are indicated. The anti-CD82 blot shows the 
integrity of the tetraspanin web. The anti-HIV-1 blot shows 
intracellular Gag-tetraspanin interactions.
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Tetraspanins, like other membrane cellular proteins
present in the viral envelope [40], can tell us about the
nature of the cellular compartment from which the virus
buds or where HIV-1 accumulates. Nowadays, the site of
HIV-1 assembly still remains controversial {i.e. mainly at
the plasma membrane [16,18,22,49], and in late endo-
somes/MVB [30,10,17,23,20,11] or in plasma membrane
invaginations [21]}. It appears that HIV-1 can accumulate
Partial inhibition of HIV-1 release using anti-tetraspanin antibodies Figure 6
Partial inhibition of HIV-1 release using anti-tetraspanin antibodies. (A) MOLT/HIV-1 cells were incubated for one 
hour with anti-tetraspanin antibodies, or with anti-VSVg, anti-CD45 or anti-Lamp2; the antibodies were then removed, and 
virus release was measured in the supernatant 3 hours post incubation with the antibodies. The results of two independent 
experiments are presented on the chart. The percentage of virus release is evaluated by RT assay in comparison to the release 
in the absence of antibodies, normalized to 100%. (B) Cell surface tetraspanin inaccessibility after treatment of MOLT/HIV-1 
cells with the anti-tetraspanin antibodies was evaluated by FACS analysis. The histograms present the surface staining of 
untreated cells and cells treated with anti-CD81 (first panel) and anti-CD45 (last panel), as indicated, at 3 hours post-viral 
release. When the proteins are expressed at the cell surface (i.e. CD81 or CD45), the antibody treatment leads to a decrease 
of the Mean Fluorescent Intensity measured. (C) Infectivity of the released virus after the treatment with anti-tetraspanin anti-
bodies. The same amount of virus was inoculated on SupT1 cells, and the resulting RT activity from de novo produced virions 
was detected (See Materials and Methods). The infectivity obtained from the "No Ab" control virus was referred as 100%. (D) 
Virus maturation (and/or retention) as well as virus release at 3 hours after anti-tetraspanin treatment in MOLT/HIV-1 cells 
were evaluated by immunoblotting using an anti-CAp24 monoclonal antibody. Cells were lysed and 50 μg of proteins were 
deposited on a gel. On the upper panel ("cell lysate") two expositions of the film are presented: at 15 seconds, only the viral 
capsid could be detected; at 1 hour, all maturation products appeared. Partial inhibition of virus release could be observed on 
the lower panel ("virus release") which is consistent with that observed by the RT assay on Fig. 4A.Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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Effects of CD81 downregulation by shRNA on viral production, HIV infectivity and Gag localization Figure 7
Effects of CD81 downregulation by shRNA on viral production, HIV infectivity and Gag localization. (A) Virus 
release was determined by measuring RT activity in the supernatant of both control and CD81 silenced MOLT/HIV-1 cells. It is 
expressed as a percentage of the control. Transduction of MOLT/HIV-1 cells with a CD81 shRNA led to an inhibition of HIV-
1 production up to 70% (3-fold). (B) Immunoblots showing intracellular CD81 silencing and its effect on viral particle release. 
MOLT/HIV-1 cells were transduced by HIV-1 based lentivectors containing a shRNA against CD81 or a control shRNA. Three 
days later, the cells were washed, and resuspended in new medium for 6 hours to allow HIV-1 virion accumulation. The result-
ing viral particles were run on a SDS-PAGE gel and immunoblotted with an anti-CAp24 antibody to reveal virus particle 
release. The cells treated with the control shRNA (lane, "sh control") or with the anti-CD81 shRNA (lane "sh CD81") were 
lysed and total cell protein content were deposited on SDS-PAGE. Resulting immunoblots were probed with different antibod-
ies as indicated. (C) Infectivity of virions issued from shRNA control or CD81 silenced MOLT/HIV-1. The same amount of 
virus was innoculated on SupT1 cells, and the resulting RT activity from de novo produced virions was detected (See Materials 
and Methods). The infectivity obtained from the shRNA control virus was referred as 100%. (D) Gag localization at the cell 
surface by immunofluorescence microscopy. After treatment with lentiviral vectors expressing shCD81 or control shRNA, 
MOLT/HIV-1 cells were fixed, permeabilized and stained for Gag (using anti-MAp17 antibody) as described in Materials and 
Methods. Two major phenotypes of Gag were observed: "clustered" – Gag is located in a cluster at one side of the cell surface; 
or "dispersed" – Gag is distributed all over the cell periphery as punctuated small dots. Patterns were quantified for CD81(-) 
cells and for the control cells; the numbers were reported on the chart.Retrovirology 2009, 6:28 http://www.retrovirology.com/content/6/1/28
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in intracellular compartments not only during virus for-
mation [14,17,20], but also after assembly at the cell sur-
face followed by an endocytosis of Gag complexes
[18,22]. This intracellular compartment where HIV-1 is
targeted is enriched in specific tetraspanins that can vary
from one cell to another. In fact, virus-containing com-
partment (VCC) was proposed to be enriched in (i) CD63
and MHC II [17,19,20] or (ii) CD9, CD53, CD81 and not
CD63 [21] for monocyte derived primary macrophages
(MDM); (iii) CD9 and CD81 [33] or (iv) CD63 and CD81
[50] for dendritic cells; and (v) CD63, CD81 and rarely
CD9 [16] for T cells. In MOLT/HIV-1 cells, the virus-con-
taining compartment seems to be enriched in CD81 and
CD82. Therefore, it appears that a different set of tet-
raspanins can be recruited in tetraspanin-enriched VCC,
where CD81 is always present. It was suggested that this
compartment is different from the conventional endo-
somes, and its formation is induced by the virus [17].
What can differ between the VCC and the LE/MVB is the
lack of acidification, permitting the persistence of infec-
tious HIV-1 particles within cells for a long time
[51,33,17]. The pH in VCC is mildly acidic due to the de-
localization of the V-ATPase which is responsible for the
acidification of the endosomal vesicles [17]. This might be
due to the recruitment of specific tetraspanins within VCC
which might counteract the V-ATPase subunits and conse-
quently ensure an optimal environment for HIV-1 forma-
tion and/or storage. Indeed, it was shown that CD63 can
associate with gastric H+, K+ ATPase and target it for deg-
radation in lysosomes [52]. This could explain why we
observed intracellular co-localization of CD63 with Gag
and Env, but no effect from anti-CD63 on HIV release.
Another explanation could be, as it was shown in previous
work, that HIV infected T cells are resistant to inhibition
of HIV-1 infection by a CD63 antibody, but sensitive to
CD63 down regulation by siRNA [32]. Thus, CD63 could
have a role in modulating the trafficking of these associ-
ated proteins and not play a direct role in HIV-1 assembly
per se. Actually, there is some discrepancy on the role of
CD63 in the late steps of HIV-1 replication, as Ruiz-
Mateos et al. have shown that CD63 is not required for
either the production or the infectivity of HIV-1 in MDM
[31] while Chen and colleagues found the opposite [32].
Tetraspanins may serve as molecular facilitators, collect-
ing proteins together [53], which suggests, in the context
of HIV-1, that tetraspanins could facilitate virus assembly
and release by bringing together Gag proteins and cellular
factors, such as Tsg101, Alix, and others which are
required at the budding site of HIV-1. Indeed, CD63 was
found to participate in protein trafficking by inducing
functional associations between protein complexes [53].
Consistent with these hypotheses, we observed the associ-
ation of HIV-1 Gag and Env with CD81 and CD82. Our
results showed that CD81 and CD82, and less CD63, are
clustered with Gag in the VCC or at the plasma mem-
brane. Thus, in reference to published views on the poten-
tial roles of cellular proteins in HIV-1 [54], either CD81/
CD82 or CD63 are incorporated into virion particles sim-
ply because of their presence at the assembly site (Figs. 1,
2, 3 and 4), or because of their interaction with Gag (Fig.
5). Therefore, either these tetraspanins were swept up into
the budding virions by this specific location (Fig. 4) but
have no function, or they are purposefully incorporated to
perform a function for the virus (Fig. 7). In the light of our
results, only CD81 appeared to be functionally important
for HIV-1 production in MOLT/HIV-1 cells (Fig. 7B). We
may speculate that CD81, CD82 and CD63 are useful for
the achievement of an optimal environment for HIV-1
assembly, while only CD81 interacts, directly or not, with
the viral protein Gag and facilitates virus formation and
egress. We report that there is an interaction between Gag
(also CAp24) and the tetraspanin web within the infected
cell (Fig. 5). It will be of interest to define the exact
domain of HIV-1 Gag that interacts with CD81. In fact, in
HTLV-1 (another human retrovirus), the MA domain of
Gag associates with CD82 and CD81 inner loops [55].
Furthermore, we show a relationship between CD81
silencing in HIV-1 producing cells and Gag de-localiza-
tion from the TEM which resulted in an inhibition of HIV-
1 release. However, the downregulation of CD81 allowed
the virus to be more infectious (Fig. 7C), suggesting that
CD81 could also act as a cellular defense response against
HIV-1 infection. Interestingly, the upregulation of CD81
mRNA synthesis was observed in primary CD4+ T lym-
phocytes infected by HIV-1 from patients [56]. Along this
line, HIV-1 replication can be positively or negatively reg-
ulated through multiple interactions with host cell pro-
teins, as we recently reported for the cellular human Disc
Large scaffold protein (hDlg1) which restricts HIV-1 infec-
tivity [57].
In conclusion, our study highlights the role of the CD81
tetraspanin in the late steps of HIV-1 replication in T lym-
phoblastic cells. Further investigations will be needed to
reveal the sequential events that lead to TEM formation,
cellular factor recruitments and the nature of the interac-
tion between CD81 and the retroviral Gag proteins in the
late steps of HIV-1 replication.
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